Sort
39,280 grants matching “leukemia”
Dissection of EWS-FLI1 oncogenic mechanisms and small molecule targeting
$363,883Jeffrey A Toretsky · Georgetown University · R01 · FY2023 · CA
Longitudinal, multimodal assessment of neuropsychological functioning in children diagnosed with high-risk acute lymphoblastic leukemia (HR-ALL): Using early changes to predict later impairment
$363,865Kristina K. Hardy · Children'S Research Institute · R01 · FY2020 · CA
Long-range function of the ERV-9 LTR in regulating globin gene switching
$363,825Dorothy Y Tuan · Augusta University · R01 · FY2012 · HL
Collaborative Pathways that Lead to Leukemia
$363,806Peter Aplan · Division Of Basic Sciences - Nci · ZIA · FY2015 · CA
Pre-clinical Studies of Therapy for Myelodysplastic Syndrome
$363,806Peter Aplan · Division Of Basic Sciences - Nci · ZIA · FY2015 · CA
Myeloid cell function in muscle injury and repair
$363,756James G Tidball · University Of California Los Angeles · R01 · FY2011 · AR
Vector Insertion and Mutagenesis in Human Hematopoiesis
$363,746Christof Von Kalle · Cincinnati Childrens Hosp Med Ctr · R01 · FY2006 · HL
KALAMAZOO COMMUNITY CLINICAL ONCOLOGY PROGRAM
$363,725West Michigan Cancer Center · U10 · FY2000 · CA
Valine as a Metabolic Modulator of Hematopoiesis
$363,715Hiromitsu Nakauchi · Stanford University · R01 · FY2019 · DK
The role of glutaminolysis as a therapeutic target in T-ALL
$363,713Daniel Herranz · Rbhs -Cancer Institute Of New Jersey · R01 · FY2020 · CA
FA pathway activities in the normal and transformed epidermis
$363,713Susanne Irmtraud Wells · Cincinnati Childrens Hosp Med Ctr · R01 · FY2018 · CA
Metabolic reprogramming in breast cancer
$363,713Zhaohui Feng · Rbhs -Cancer Institute Of New Jersey · R01 · FY2020 · CA
Re-purposing Oncolytic Virotherapy to Re-invigorate CAR T Cell Therapy for Solid Tumors.
$363,713Richard G Vile · Mayo Clinic Rochester · R01 · FY2023 · CA
The role of glutaminolysis as a therapeutic target in T-ALL
$363,713Daniel Herranz · Rbhs -Cancer Institute Of New Jersey · R01 · FY2022 · CA
Mechanism of non-oncogene addiction
$363,713Mohammad Azam · Cincinnati Childrens Hosp Med Ctr · R01 · FY2021 · CA
Targeting Chk1 in Acute Myeloid Leukemia
$363,713Larry M Karnitz · Mayo Clinic Rochester · R01 · FY2016 · CA
The role of glutaminolysis as a therapeutic target in T-ALL
$363,713Daniel Herranz · Rbhs -Cancer Institute Of New Jersey · R01 · FY2021 · CA
Mechanism of non-oncogene addiction
$363,713Mohammad Azam · Cincinnati Childrens Hosp Med Ctr · R01 · FY2018 · CA
FA pathway activities in the normal and transformed epidermis
$363,713Susanne Irmtraud Wells · Cincinnati Childrens Hosp Med Ctr · R01 · FY2020 · CA
FA pathway activities in the normal and transformed epidermis
$363,713Susanne Irmtraud Wells · Cincinnati Childrens Hosp Med Ctr · R01 · FY2021 · CA
Re-purposing Oncolytic Virotherapy to Re-invigorate CAR T Cell Therapy for Solid Tumors.
$363,713Richard G Vile · Mayo Clinic Rochester · R01 · FY2025 · CA
Targeting Chk1 in Acute Myeloid Leukemia
$363,713Larry M Karnitz · Mayo Clinic Rochester · R01 · FY2018 · CA
Mechanism of non-oncogene addiction
$363,713Mohammad Azam · Cincinnati Childrens Hosp Med Ctr · R01 · FY2020 · CA
Metabolic reprogramming in breast cancer
$363,713Zhaohui Feng · Rbhs -Cancer Institute Of New Jersey · R01 · FY2021 · CA
Metabolic reprogramming in breast cancer
$363,713Zhaohui Feng · Rbhs -Cancer Institute Of New Jersey · R01 · FY2018 · CA